# Famitresgene autoleucel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/famitresgene-autoleucel

> The FDA approved famitresgene autoleucel, sponsored by Adaptimmune Therapeutics PLC (ADAPY), on Aug 2024 for unresectable/metastatic synovial sarcoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | famitresgene autoleucel |
| Codes |  |
| Sponsor | Adaptimmune Therapeutics PLC (ADAPY) https://sec-api.dev/companies/adapy/catalysts |
| Indications | unresectable/metastatic synovial sarcoma |
| Modality | cell_therapy |
| FDA designations | accelerated |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: unresectable/metastatic synovial sarcoma.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001558370-25-003544): "In August 2024 we received accelerated approval from the FDA for TECELRA (famitresgene autoleucel or afami-cel) for adults with unresectable/metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02 eligible, and whose tumor expresses MAGE-A4 as determined by FDA-approved diagnostics." https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/famitresgene-autoleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Famitresgene autoleucel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/famitresgene-autoleucel

```bibtex
@misc{secapidev_pdufa_famitresgene_autoleucel_20261116,
  title        = {Famitresgene autoleucel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/famitresgene-autoleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_famitresgene_autoleucel_20261116","title":"Famitresgene autoleucel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/famitresgene-autoleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
